

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-175)

UMIBECESTAT

PRONUNCIATION

ue" mi bes' e stat


THERAPEUTIC CLAIM

Treatment of Alzheimer's disease

CHEMICAL NAMES

1. 2-Pyridinecarboxamide, *N*-[6-[(3*R*,6*R*)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2*H*-1,4-oxazin-3-yl]-5-fluoro-2-pyridinyl]-3-chloro-5-(trifluoromethyl)-
2. *N*-{6-[(3*R*,6*R*)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2*H*-1,4-oxazin-3-yl]-5-fluoropyridin-2-yl}-3-chloro-5-(trifluoromethyl)pyridine-2-carboxamide

STRUCTURAL FORMULA



MOLECULAR FORMULA

C<sub>19</sub>H<sub>15</sub>ClF<sub>7</sub>N<sub>5</sub>O<sub>2</sub>

MOLECULAR WEIGHT

513.8

TRADEMARK

None as yet

SPONSOR

Novartis Pharma AG

CODE DESIGNATIONS

NVP-CNP520-NXA; CNP520-NXA

CAS REGISTRY NUMBER

1387560-01-1

UNII

4612B80545

WHO NUMBER

10872

SCS